Aclidinium Bromide Suppliers & Bulk Manufacturers
Available Forms: inhalation powder
Available Strengths: 400 mcg
Reference Brands: Tudorza Pressair (USA), Eklira Genuair (EU)
Category:
Respiratory Disorder
Aclidinium Bromide is available in inhalation powder
and strengths such as 400 mcg.
Sourced from GMP-certified and ISO-compliant manufacturers, this API meets
global pharmacopeia standards (USP/EP/JP as applicable). Ideal for pharmaceutical
formulation and commercial manufacturing, Aclidinium Bromide is supplied in
bulk quantities with complete regulatory support including DMF, COA, and MSDS.
|
Technical Specifications & Supply Details
|
| Lead Time |
7 to 60 days (depending on batch size & schedule) |
| MOQ |
As per manufacturer’s batch size |
| COA |
Available with every batch |
| Regulatory Dossier / DMF |
Available upon request |
| Export Documentation |
FSC, COA, Manufacturing License, Product Permission |
| Standards |
IP, BP, USP |
| Certifications |
WHO-GMP, EU-GMP, USFDA (as applicable) |
Aclidinium Bromide can be exported to over 30 countries across Asia, Africa, Europe,
and Latin America. Flexible packaging, competitive pricing, and a verified supplier
network make Pharmatradz a trusted sourcing partner for pharmaceutical companies
and contract manufacturers worldwide.
Product Description:
Aclidinium bromide is a long-acting muscarinic antagonist (LAMA) administered via inhalation and approved for use as a maintenance therapy in patients with chronic obstructive pulmonary disease (COPD). It received regulatory approval in the United States in July 2012 for the long-term management of airflow limitation associated with COPD, including chronic bronchitis and emphysema. By selectively blocking muscarinic receptors in the airway smooth muscle, aclidinium bromide produces sustained bronchodilation, helping to improve lung function and reduce respiratory symptoms.
Clinical evidence indicates that aclidinium bromide can improve quality of life in patients with COPD and reduce the risk of disease-related hospitalizations. While it provides effective symptom control and supports daily respiratory function, studies have not shown a significant impact on overall mortality or on the frequency of systemic corticosteroid use. Comparisons with other long-acting muscarinic antagonists, such as tiotropium, suggest similar therapeutic outcomes, although clear superiority over other agents in the LAMA class has not been conclusively established.
Aclidinium bromide is intended for regular maintenance treatment and is not suitable for the relief of acute bronchospasm or sudden breathing difficulties.
Disclaimer: By continuing to browse, you agree to the terms of use of this website and the Trade Marks displayed, in compliance with the provisions of the Trademark Act, 1999, Section 30 and 30(1) under 'Fair use.'
The Trade Mark owner has been correctly identified under the heading Manufacturer / TM Owner as required by the Act.
Back to Listing